Arbutus Biopharma Corporation
NASDAQ:ABUSBiotechnology
Healthcare
$4.07 +1.13%
+$0.05 today
- Market cap
- $623.90M
- Beta
- 0.63
- P/E (TTM)
- 5.4
- EPS (TTM)
- $0.83
52W Low $3.04High $5.10
Volume 2.44M
Average 1.76M
Income Statement
Follow revenue through to earnings.
Revenue
$14.08M
FY 2025 · Annual
+128.2% YoYOperating Income
-$27.05M
FY 2025 · Annual
Net Income
-$33.50M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 10.99M | 39.02M | 18.14M | 6.17M | 14.08M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 363K |
| Gross Profit | 10.99M | 39.02M | 18.14M | 6.17M | 13.72M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 97.4% |
| Research & Development | 65.5M | 84.41M | 73.7M | 54.04M | 25.24M |
| Selling, General & Admin | 17.14M | 17.83M | 22.48M | 22.11M | 15.89M |
| Operating Expenses | 84.51M | 104.48M | 96.24M | 82.49M | 40.77M |
| Depreciation & Amortization | 1.75M | 1.43M | 1.4M | 1.38M | 363K |
| EBITDA | (71.64M) | (61.86M) | (70.99M) | (68.4M) | (33.04M) |
| EBITDA Margin | -652.0% | -158.5% | -391.3% | -1108.5% | -234.6% |
| Operating Income | (73.52M) | (65.46M) | (78.1M) | (76.32M) | (27.05M) |
| Operating Margin | -669.1% | -167.8% | -430.5% | -1236.7% | -192.1% |
| Interest Income | 127K | 2.19M | 5.69M | 6.59M | 4.07M |
| Interest Expense | 2.86M | 1.73M | 459K | 137K | 97K |
| Other Income / Expenses | (2.73M) | 444K | 5.25M | 6.4M | (6.45M) |
| Income Before Tax | (76.25M) | (65.01M) | (72.85M) | (69.92M) | (33.5M) |
| Pre-Tax Margin | -693.9% | -166.6% | -401.6% | -1133.0% | -237.9% |
| Income Tax Expense | 0 | 4.44M | 0 | 0 | 0 |
| Net Income | (76.25M) | (69.46M) | (72.85M) | (69.92M) | (33.5M) |
| Net Margin | -693.9% | -178.0% | -401.6% | -1133.0% | -237.9% |
| EPS (Basic) | (0.73) | (0.46) | (0.44) | (0.38) | (0.17) |
| EPS (Diluted) | (0.73) | (0.46) | (0.44) | (0.38) | (0.17) |
| 106.24M | 150.94M | 165.96M | 185.61M | 191.6M | |
| 106.24M | 150.94M | 165.96M | 185.61M | 191.6M |
ABUS Earnings Waterfall · TTM
NASDAQ:ABUS · Revenue to Net Income
Key Ratios
EPS$0.82
Gross Margin99.2%
Net Margin-425.7%
P/E Ratio-7.4
P/S Ratio645.7
Analysis
$191.4M of revenue converted into $160.7M of net income for the selected period. Gross margin is 99.2% and net margin is -425.7%, showing how much revenue survives after costs and taxes. EPS is $0.82, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 10, 2026 | |
| 8-K | Current report | Nov 10, 2026 | |
| SC 13G/A | SC 13G/A filing | Oct 27, 2026 | |
| 8-K | Current report | Oct 22, 2026 |
How much revenue does ABUS generate?
Arbutus Biopharma Corporation (ABUS) reported $14.08M of revenue in fiscal 2025.
Is ABUS profitable?
Arbutus Biopharma Corporation (ABUS) reported -$33.50M of net income, with a net margin of -237.9%.
Continue the stock analysis
Jump to another research area for this company.